The introduction of polynucleotide-based therapy into the cosmetic/aesthetic arena heralds a significant step in the way in which practitioners are now able to bio-revitalise and bio-rejuvenate a patient's skin in a significant and longer-lasting manner.
How it works
The basic unit of the polynucleotide-based injectable relies on long chains of highly purified nucleotides which form a series of highly stable alpha helixes. The hypoallergenic polynucleotides are contained within a non-hyaluronic acid clear gel carrier.
What about its mechanisms? Once injected intra-dermally, the high-purity polynucleotides target the dermal fibroblast to reduce levels of local free radicals, increase the synthesis of collagen and elastin appreciably, increase hydration through attracting water molecules local to the injection site and increase the viability of the targeted fibroblasts (Colangelo et al, 2021).
The impact
The overall impact clinically of high-purity polynucleotides when administered in skin is an improvement in intrinsic skin quality, with increased skin glow, reduction in pore size, improved smoothness, greater elasticity, improved humectant capacity and skin turgor. The treatment can be applied to patients who require skin maintenance, skin rescue and repair, wound healing, scar improvement and revision, reduced inflammation and importantly, skin ageing. Whether a patient has normal or sensitive skin, protocols have been devised through extensive research and peer-review that allow polynucleotides to be effective and well tolerated in either clinical situation (Cavallini et al, 2021; Cavallini et al, 2022).
» The overall impact clinically of high-purity polynucleotides when administered in skin is an improvement in intrinsic skin quality, with increased skin glow, reduction in pore size, improved smoothness, greater elasticity, improved humectant capacity and skin turgor «
The versatility
The versatility of the high purity polynucleotide is defined by a well formulated portfolio which allows the face, neck, décolleté, hands, abdomen, thighs and under-eye area to be treated effectively as part of evidenced-based consensus recommended clinical protocols. This can be tailored for each individual patient through a consultation and comprehensive assessment of the patient by their treating clinician (Cavallini et al, 2021).
‘Polynucleotides—what's the fuss?’ It's easy to see why from its efficacy, ease of use, safety profile and bespoke patient-orientated treatment. It now allows clinicians to do more for their patients than ever before.